Archigen Biotech Limited is a joint venture formed by AstraZeneca and Samsung BioLogics for the research, clinical development, manufacturing, and global commercialization of biological pharmaceuticals.
Archigen’s mission is to develop affordable high quality biopharmaceutical products to address the unmet medical needs of patients worldwide.
Archigen Biotech was established in England in 2014. Our scientists have many years of experience in clinical research and pharmaceutical development.
Developing high quality biopharmaceutical products requires orchestration of multiple subject matter experts. Archigen combines in-house expertise with a panel of leading global Contract Research Organizations and Contract Manufacturing Organizations to ensure efficient execution of drug development activities.
Archigen’s flagship product is SAIT101, which is in development for hematological and autoimmune disease indications.